Onconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor Conference

Rhea-AI Summary

Onconova Therapeutics (NASDAQ: ONTX), a clinical-stage biopharmaceutical company, announced participation in the MedInvest Oncology Investor Conference in New York on December 14-15, 2022. CEO Steven M. Fruchtman will present a corporate overview on December 14 at 9:40 a.m. ET. The management team will also hold one-on-one meetings that day. Onconova focuses on developing targeted anti-cancer agents, including narazaciclib and rigosertib, both of which are currently in clinical studies.

NEWTOWN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that it will participate in the MedInvest Oncology Investor Conference being held in New York, NY on December 14-15, 2022.

Steven M. Fruchtman, M.D., President and Chief Executive Officer, will present a corporate overview at the conference on Wednesday, December 14^th at 9:40 a.m. ET. Dr. Fruchtman and other members of the Onconova management team will also be available for one-on-one meetings at the conference on December 14^th.

Those interested in requesting a one-on-one meeting can submit a registration request using the conference website: https://www.medinvestconferences.com/register.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.

Onconova’s product candidate rigosertib is being studied in an investigator-sponsored study program, including in a dose-escalation and expansion Phase 1/2a investigator-sponsored study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.

For more information, please visit www.onconova.com.

Company Contact:
Mark Guerin
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/

Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com

FAQ

When is Onconova Therapeutics participating in the MedInvest Oncology Investor Conference?

Onconova Therapeutics will participate in the MedInvest Oncology Investor Conference on December 14-15, 2022.

Who will present at the MedInvest Oncology Investor Conference for ONTX?

CEO Steven M. Fruchtman will present a corporate overview for Onconova Therapeutics at the conference.

What time is Onconova's presentation at the MedInvest Oncology Investor Conference?

Onconova's presentation is scheduled for December 14 at 9:40 a.m. ET.

What are the primary products being developed by Onconova Therapeutics?

Onconova is developing narazaciclib and rigosertib, both targeted anti-cancer agents.

What types of studies are Onconova's products currently undergoing?

Onconova's products are currently being evaluated in Phase 1 dose-escalation and expansion studies.